Truist Securities Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Biomarin Pharmaceutical but lowered its price target from $118 to $90.
September 17, 2024 | 2:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities has maintained a Buy rating on Biomarin Pharmaceutical but lowered its price target from $118 to $90, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in Biomarin's potential, but the lowered price target reflects a more cautious outlook, likely due to revised expectations or market conditions. This could lead to short-term downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100